Tsui DCC, Aisner D, Nijmeh H, Bao L, et al. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer 2021 Jul 3. pii: S1525-7304(21)00179.
PMID: 34330640